Cardiovascular & Metabolic Diseases

Breath biomarkers could lead to non-invasive detection and monitoring for liver disease, diabetes, kidney disease, heart failure and other cardiovascular and metabolic diseases

FIND OUT MORE

Webinar: Prof. Luis Mendez at BBCon 2023

Applications of Breath Analysis: Approaching Complementary Studies for Timely and Accurate Diagnosis of Cirrhosis. From Primary Care to Specialty Consultation.

VIEW PRESENTATION

Article: Insights into potential VOC biomarkers of diabetes

Non-invasive breath testing offers an attractive alternative to currently available diabetes tests for diagnosis and ongoing monitoring

READ REVIEW

Article: Examining candidate breath biomarkers for kidney disease

A non-invasive breath test could allow for cheaper screening and earlier intervention, when damage is less severe

VIEW PUBLICATION

Case Study: Could acetone be a biomarker of heart failure?

Current biomarkers of heart function are very invasive but evidence suggests breath acetone could be useful for both diagnosis and prognosis

READ CASE STUDY

Paper: EVOC Breath Testing Maximizes Classification Performance for Subjects with Cirrhosis

A study demonstrating that dynamic limonene breath testing enhances diagnostic performance for cirrhosis compared to static testing, and could be implemented in primary care

VIEW PAPER

In developed countries, driven by poor diet and low exercise, cardiovascular and metabolic diseases are on the rise, with fatty liver diseases quietly reaching epidemic levels across both adults and children. In the US approximately 30% of adults and as many as 1 in 10 children suffer from some form of liver disease, leading to direct and societal costs estimated at almost $300B per year.

While 90% of liver disease is preventable if caught early, most people have little to no symptoms until the disease has advanced, so the majority of patients are diagnosed at the point of liver failure. There is therefore a critical need for earlier detection when lifestyle changes and therapeutics can be effectively deployed, and the number of patients experiencing severe symptoms reduced.

We are developing a breath test capable of detecting liver disease early before any symptoms show, involving the use of an Exogenous Volatile Organic Compound (EVOC®) Probe known as limonene to probe the function of the liver. Our work in this area has been highly successful and indicates that breath testing in this way may be a suitable test for screening the general population.

Case Studies

A detailed look at some of the research studies investigating biomarkers for different types of cardiovascular & metabolic diseases.

PARTNERS

We’re working on cardiovascular & metabolic diseases with these groups:

FURTHER READING

Other recommended reading:

Cardiometabolic Diseases Infographic

Blog

Articles published on our blog related to cardiovascular & metabolic diseases.

Cardiometabolic Disease and the Gut Microbiome
The Intersection between Liver Disease and the Microbiome
Could breath acetone be a potentially useful biomarker for heart failure?
Why are CYP enzymes a key focus for liver disease research?
Examining candidate breath biomarkers for kidney disease
Breath biomarkers for cardiometabolic diseases
Advancing early detection for liver diseases including NAFLD and NASH with Breath Biopsy
Cardiometabolic Disease and the Gut Microbiome
The Intersection between Liver Disease and the Microbiome
Could breath acetone be a potentially useful biomarker for heart failure?
Why are CYP enzymes a key focus for liver disease research?
Examining candidate breath biomarkers for kidney disease
Breath biomarkers for cardiometabolic diseases
Advancing early detection for liver diseases including NAFLD and NASH with Breath Biopsy

On-Demand Webinar Available Now:

Watch to learn how breath analysis can be used to gain a deeper understanding of liver disease and potentially lead to earlier diagnosis.